FDA Brief

Warning letters Drugs

FDA warning letter to

Scope Health Inc

High riskIssued Jul 9, 2025Posted Jul 15, 2025Center for Drug Evaluation and Research (CDER)

FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

What happened

On August 28, 2024, FDA reviewed Scope Health's product labeling, including optase.com, where the ophthalmic drug products are available for purchase in the United States without a prescription. FDA found the products are unapproved new drugs and that several are misbranded, including a missing required warning on Dry Eye Intense Drops (multi-use bottle). FDA also says some ingredients are not permitted for OTC ophthalmic demulcent or emollient products under monograph M018.

What FDA found

  1. The eye products are unapproved new drugs because FDA says they are not generally recognized as safe and effective and have no FDA-approved applications.

    FD&C Act sections 505(a) and 301(d), 21 U.S.C. 355(a) and 331(d)
  2. MGD Advanced Dry Eye Drops, Dry Eye Intense Drops, and Allegro Eye Drops contain ingredients FDA does not allow as active ingredients in OTC ophthalmic demulcent products under monograph M018.12.

    OTC Monograph M018.12; FD&C Act section 505G
  3. HYLO Night Eye Ointment contains vitamin A, which FDA does not allow as an active ingredient in OTC ophthalmic emollient products under M018.14.

    OTC Monograph M018.14; FD&C Act section 505G
  4. Dry Eye Intense Drops (multi-use bottle) lacks the required warning “If solution changes color or becomes cloudy, do not use.”

    FD&C Act section 502(f)(2), 21 U.S.C. 352(f)(2); M018.60
  5. Allegro Eye Drops, MGD Advanced Dry Eye Drops, Dry Eye Intense Drops (multi-use and single dose), and HYLO Night Eye Ointment are misbranded because they do not meet section 505G requirements and are not FDA-approved.

    FD&C Act section 502(ee), 21 U.S.C. 352(ee)

What FDA wants

FDA asks Scope Health to investigate and correct the violations, prevent recurrence, and respond in writing within 15 working days with steps taken, documentation, or reasoning if it disagrees. Send the response to FDAAdvisory@fda.hhs.gov with the firm name and identifier 695085.

Who should pay attention

  • retailers and online marketplaces selling eye-care products
  • brands that distribute OTC ophthalmic products
  • consumers using dry eye or blepharitis products

This is a summary. Read the original letter on fda.gov.

Scope Health Inc's FDA history

Recalls in the last 12 months

May 6 Class II SCOPE HEALTH
Drug
Optase Dry Eye Intense Drops (Glycerin 0.2%), packaged in 0.33 fl oz, Sterile, Manufactured for Scope Health Inc., 79 Madison Ave., 8th Floor, New York, NY 10016, USA, NDC 72972-002-01.
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk